Postbiotic CP2305 Shows Stress Reduction Potential, Opening Mental Wellness Category
A Japanese study highlights *Lactobacillus gasseri* CP2305's efficacy in reducing stress and increasing alpha brain activity, positioning it as a commercially viable ingredient for the burgeoning mental wellness supplement market. Brand owners should assess formulation viability and market differentiation.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
New research from Asahi Quality and Innovations in Japan indicates that a single dose of heat-treated Lactobacillus gasseri CP2305, a postbiotic, significantly increases brain alpha activity and enhances parasympathetic nervous system function in healthy adults. These physiological changes are associated with relaxation and reduced mental stress, providing a strong scientific basis for its application in mental wellness supplements.
The double-blind, placebo-controlled trial involved 28 participants, demonstrating significant improvements in subjective mental stress scores and increased serotonin secretion. This outcome underscores the ingredient's potential impact on the gut-brain axis, an area of growing consumer interest. The study specifically attributes these benefits to the postbiotic form of CP2305, highlighting the importance of specific processing methods for achieving targeted functional effects. This distinguishes CP2305 from live probiotic applications, potentially simplifying formulation and stability challenges for manufacturers.
Asahi's findings position CP2305 as a promising functional food ingredient for mental health. The market for mood and stress support supplements is expanding, driven by heightened consumer awareness of the gut-brain connection and demand for non-pharmaceutical interventions. This research provides a robust evidence base for product development, moving beyond anecdotal claims to clinically validated benefits. However, further research is required to fully elucidate the precise mechanisms of action and to explore broader applications in diverse populations and chronic stress conditions, impacting the scope of permissible claims under regulations like EFSA.
For contract manufacturers, this presents an opportunity to innovate in ingredient sourcing and formulation. Developing delivery systems that protect the integrity of heat-treated postbiotics, while optimising bioavailability, will be key to creating effective and compliant end products. The ingredient's stability characteristics, owing to its heat-treated nature, could offer advantages in product shelf-life and processing compared to live bacterial cultures.
What this means for United Kingdom
UK brand owners should immediately assess *Lactobacillus gasseri* CP2305 for new product development within the mental wellness category, which saw an estimated 8% growth in 2023. Compliance with UK Advertising Standards Authority (ASA) guidelines for gut-brain claims will be critical, necessitating clear substantiation beyond the initial study. Manufacturers must secure reliable supply chains for this specific postbiotic, negotiating favourable MOQs and lead times from Japanese suppliers. Early adoption could yield a first-mover advantage in a competitive market, allowing differentiation in Boots or Holland & Barrett. Regulatory teams should prepare for Novel Food application or assessment if not already on the market, ensuring all dossier requirements are met to avoid market delays. Reformulation windows for existing stress products should be considered for integration of CP2305.
Many leading brands in this category are manufactured in partnership with Supplement Factory.